BioSpace News Archive

Community-based 3D printing makers mobilize to solve PPE shortage, helping protect police, fire and rescue, and other critical essential service providers from COVID-19 virus

Intense Engineering proudly introduces the HSP-1000. Precision engineered, purpose-built, and based on their proven clinical/diagnostic equipment platform, the fully automated HSP-1000 brings speed, safety, and accuracy to COVID-19 sample tube testing.

OrthoPediatrics Corp. announced that Mark Throdahl, President & Chief Executive Officer, Fred Hite, Chief Financial Officer, and Dave Bailey, Executive Vice President, are scheduled to participate in the 6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series.

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents

Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended March 31, 2020.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, announced that it intends to offer its common shares in an underwritten public offering.

7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced the company will be participating in the upcoming BofA Securities 2020 Health Care Conference.

MacroGenics, Inc. announced three clinical presentations at the American Society of Clinical Oncology upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.

Mersana Therapeutics, Inc. announced that it will host a conference call and webcast on Friday, May 8, 2020 at 8:00 a.m. ET to report financial results for the first quarter ended March 31, 2020 and provide business updates, including details on its XMT-1536 Phase 1 interim dose expansion data disclosure and poster session at the upcoming American Society of Clinical Oncology’s 2020 Virtual Scientific Program.